Company Name
Immunome Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US45257U1088
CIK:
0001472012
CUSIP:
45257U108
Currency:
USD
Full Time Employees:
168
Phone:
425 939 7410
Website:
https://immunome.com
Fiscal Year End:
December
IPO Date:
Oct 02, 2020
Description:
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Address:
18702 North Creek Parkway, Bothell, WA, United States, 98011